Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

Takaaki ONO, MD PhD, Naoto Takahashi, MD PhD, Masahiro Kizaki, MD, Tatsuya Kawaguchi, MD, Ritsuro Suzuki, MD PhD, Kazuhito Yamamoto, Kazunori Ohnishi, MD, Tomoki Naoe, MD PhD, Itaru Matsumura, MD PhD

Blood (2019) 134 (Supplement_1): 4149.

https://doi.org/10.1182/blood-2019-122092

Published: 2019

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities

Naoto Takahashi, MD PhD, Tomoko Yoshioka, MD, Masahiro Kizaki, MD, Tatsuya Kawaguchi, MD, Ritsuro Suzuki, MD PhD, Kazuhito Yamamoto, Kazunori Ohnishi, MD, Tomoki Naoe, MD PhD, Itaru Matsumura, MD PhD

Blood (2019) 134 (Supplement_1): 1640.

https://doi.org/10.1182/blood-2019-123337

Published: 2019

Journal Articles

Gene Mutation Profile and Risk Stratification in AML1-ETO-Positive Acute Myeloid Leukemia Based on Next-Generation Sequencing

Guopan Yu, Changxin Yin, Fuqun Wu, Ling Jiang, Zhongxin Zheng, Dan Xu, Jiaheng Zhou, Xuejie Jiang, MD, Qifa Liu, MD, Fanyi Meng

Blood (2018) 132 (Supplement 1): 5249.

https://doi.org/10.1182/blood-2018-99-113494

Published: 2018

Journal Articles

Cytogenetics-Based Risk Prediction of Blastic Transformation of CML Treated with Tyrosine Kinase Inhibitors

Zimu Gong, MD, L. Jeffrey Medeiros, MD, Jorge E. Cortes, MD, Wei Wang, MD PhD, Hagop M. Kantarjian, MD, Shimin Hu

Blood (2017) 130 (Supplement 1): 247.

https://doi.org/10.1182/blood.V130.Suppl_1.247.247

Published: 2017

Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Blood (2017) 130 (Supplement 1): 899.

https://doi.org/10.1182/blood.V130.Suppl_1.899.899

Published: 2017

Journal Articles

Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML

Ghayas C. Issa, MD, Hagop M. Kantarjian, MD, Feng Wang, PhD, Graciela Nogueras González, Gautam Borthakur, MD, Guilin Tang, MD, Carlos E. Bueso-Ramos, MD PhD, Rashmi Kanagal-Shamanna, MD, Juliana Elisa Hidalgo Lopez, MD, Chong Zhao, Marcus Coyle, Koichi Takahashi, MD, Preetesh Jain, MBBS,MDDM,PhD, Farhad Ravandi, MBBS, Tapan Kadia, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Andrew Futreal, PhD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 47.

https://doi.org/10.1182/blood.V130.Suppl_1.47.47

Published: 2017

Journal Articles

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Natalia Lazorko, MD, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Irina Martynkevich, Mikhail Fominykh, MD, Anna Silyutina, MD, Katerina Ovsiannikova, Nadia Siordia, MD, Andrey Zaritskey, Elena Machulaytene, MD

Blood (2017) 130 (Supplement 1): 5255.

https://doi.org/10.1182/blood.V130.Suppl_1.5255.5255

Published: 2017

Journal Articles

Role of Somatic Mutations in Clonal Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Phase

Chetasi Talati, MD, Leidy Isenalumhe, MD, Andrew Kuykendall, MD, Bijal D. Shah, MD, Julio C. Chavez, MD, Mohammad Omar Hussaini, MD, Javier Pinilla-Ibarz, MD PhD, Kendra L. Sweet, MD

Blood (2017) 130 (Supplement 1): 1587.

https://doi.org/10.1182/blood.V130.Suppl_1.1587.1587

Published: 2017

Journal Articles

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment

Ghayas C. Issa, Hagop M. Kantarjian, Graciela Nogueras Gonzalez, Gautam Borthakur, Guilin Tang, William Wierda, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Tapan Kadia, Keyur Patel, Raja Luthra, Alessandra Ferrajoli, Guillermo Garcia-Manero, Mary Beth Rios, Sara Dellasala, Elias Jabbour, Jorge E. Cortes

Blood (2017) 130 (19): 2084–2091.

https://doi.org/10.1182/blood-2017-07-792143

Published: 2017

Includes: Supplemental data

Journal Articles

Prognostic relevance of CCAs/Ph − in CML settled

Rüdiger Hehlmann

Blood (2017) 130 (19): 2046–2047.

https://doi.org/10.1182/blood-2017-09-804054

Published: 2017

Journal Articles

Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality

Nicholas J. Short, MD, Elias J. Jabbour, MD, Koji Sasaki, MD, Heidi Ko, MD, Farhad Ravandi, MD, C. Cameron Yin, MD PhD, Maria R. Khouri, Jorge E. Cortes, MD, Rebecca Garris, MS, Susan M. O'Brien, MD, Keyur P. Patel, MD PhD, Guillermo Garcia-Manero, MD, Deborah A Thomas, MD, Naval Daver, MD, Kiran Naqvi, MD, Prithviraj Bose, MD, Nitin Jain, MD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 1737.

https://doi.org/10.1182/blood.V128.22.1737.1737

Published: 2016

Journal Articles

Prognostic Significance of 11q23/ MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

Erin M. Guest, MD, Betsy A. Hirsch, PhD, E. Anders Kolb, MD, Todd A. Alonzo, PhD, Robert Gerbing, BS, Richard Aplenc, MD PhD, Jessica Pollard, MD, Lillian Sung, MD PhD FRCPC, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH, Susana C. Raimondi, PhD

Blood (2016) 128 (22): 1211.

https://doi.org/10.1182/blood.V128.22.1211.1211

Published: 2016

Journal Articles

Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Mikhail Fominykh, MD, Vasily Shuvaev, MD, Irina Martynkevich, DSc, Oleg Shukhov, MD, Ekaterina Chelysheva, MD, Anna G Turkina, Prof., MD, Kudrat Abdulkadyrov, Prof., MD PhD

Blood (2016) 128 (22): 5437.

https://doi.org/10.1182/blood.V128.22.5437.5437

Published: 2016

Journal Articles

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Wei Wang, Jorge E. Cortes, Guilin Tang, Joseph D. Khoury, Sa Wang, Carlos E. Bueso-Ramos, Joseph A. DiGiuseppe, Zi Chen, Hagop M. Kantarjian, L. Jeffrey Medeiros, Shimin Hu

Blood (2016) 127 (22): 2742–2750.

https://doi.org/10.1182/blood-2016-01-690230

Published: 2016

Includes: Supplemental data

Journal Articles

Cytogenetics in CML: more important than you think

François Guilhot

Blood (2016) 127 (22): 2661–2662.

https://doi.org/10.1182/blood-2016-04-708206

Published: 2016

Journal Articles

Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in State of Qatar

Nader I Al-Dewik, BSc, MSc, PhD, Andrew Jewell, PhD, Mohamed A. Yassin, MBBS ,MSc,CABM,FACP, Hisham Morsi, MD DiSc, PhD

Blood (2015) 126 (23): 4846.

https://doi.org/10.1182/blood.V126.23.4846.4846

Published: 2015

Journal Articles

The Aberrations of Cytogenetics and Molecular Genetics in Core Binding Factor Acute Myeloid Leukemia

Aining Sun, PhD, Ding Chao, Suning Chen, Haiping Dai, Wu Depei, MD

Blood (2015) 126 (23): 4802.

https://doi.org/10.1182/blood.V126.23.4802.4802

Published: 2015

Journal Articles

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

Ghayas C. Issa, MD, Hagop M. Kantarjian, MD, Elias Jabbour, Gautam Borthakur, MD, Srdan Verstovsek, MD, Sherry Pierce, BSN, BA, William Wierda, MD PhD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Farhad Ravandi, MD, Sara Emogene DellaSala, BS, Jorge E. Cortes, MD

Blood (2015) 126 (23): 1577.

https://doi.org/10.1182/blood.V126.23.1577.1577

Published: 2015

Journal Articles

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

Wei Wang, Jorge E. Cortes, Pei Lin, Michael W. Beaty, Di Ai, Hesham M. Amin, Timothy J. McDonnell, Chi Young Ok, Hagop M. Kantarjian, L. Jeffrey Medeiros, Shimin Hu

Blood (2015) 126 (14): 1699–1706.

https://doi.org/10.1182/blood-2015-05-646489

Published: 2015

Includes: Supplemental data

NARROW

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities

Gene Mutation Profile and Risk Stratification in AML1-ETO-Positive Acute Myeloid Leukemia Based on Next-Generation Sequencing

Cytogenetics-Based Risk Prediction of Blastic Transformation of CML Treated with Tyrosine Kinase Inhibitors

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Role of Somatic Mutations in Clonal Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Phase

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment

Prognostic relevance of CCAs/Ph − in CML settled

Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality

Prognostic Significance of 11q23/ MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Cytogenetics in CML: more important than you think

Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in State of Qatar

The Aberrations of Cytogenetics and Molecular Genetics in Core Binding Factor Acute Myeloid Leukemia

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only